Ultomiris 300mg/30ml (Ravulizumab-cwvz Vials) 300 mg/30ml

Ultomiris 300mg/30ml (ravulizumab-cwvz) is a prescription medication available in vial form for intravenous use. This sterile solution is used to treat certain blood disorders by modifying immune system activity. Store between 2-8°C to maintain potency.

Strength

300 mg/30ml

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Alexion Pharmaceuticals Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ultomiris 300mg/30ml is used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), rare blood conditions. It works by targeting specific proteins in the immune system to reduce red blood cell destruction. People often search for 'what is Ultomiris used for' or 'ravulizumab-cwvz uses' when researching this treatment.

Side Effects

This medication helps reduce symptoms like fatigue and shortness of breath associated with PNH and aHUS. Patients may experience improved energy levels and reduced need for blood transfusions over time. Common effects include infusion-related reactions such as headache or nausea during administration.

Precautions & Warnings

Ultomiris requires careful handling and should only be administered by healthcare professionals. Keep vials refrigerated between 2-8°C and protect from light. Do not shake the vial; gently swirl if needed. Always check expiration dates before use to ensure safety.

Avoid Interactions

No specific drug interactions have been established, but caution is advised when combining with other medications that affect the immune system. Avoid live vaccines during treatment, as immune response may be altered. Consult a healthcare provider before starting any new medications while using Ultomiris.

Frequently Asked Questions

It is used for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

It is given as an intravenous infusion by a healthcare professional.

No, it must be refrigerated between 2-8°C and protected from light.

Some patients may experience headache or nausea during infusion.

Yes, this medication requires a prescription from a licensed healthcare provider.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.